FDA
FDA biologics chief Vinay Prasad to leave agency at end of April
Riportato dall'IA Immagine generata dall'IA Verificato
Dr. Vinay Prasad, who leads the FDA division that oversees vaccines and other biological products, will leave the agency at the end of April, FDA Commissioner Marty Makary told staff in an email. It will be Prasad’s second departure in less than a year after a brief exit last summer amid clashes over high-profile drug and vaccine reviews.
Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.
Riportato dall'IA
The U.S. Food and Drug Administration approved FILSPARI, developed by Travere Therapeutics, as the first medicine for focal segmental glomerulosclerosis (FSGS). Travere announced the approval on April 13, 2026. Company executives held a business update conference call that evening to discuss the milestone.
The U.S. Supreme Court unanimously ruled on June 13, 2024, that the FDA's approval of the abortion pill mifepristone is valid and remains in effect. The decision dismissed challenges from anti-abortion groups, affirming the agency's regulatory authority. This ruling ensures continued access to medication abortion, which accounts for more than half of U.S. abortions.
Riportato dall'IA
The U.S. Food and Drug Administration has finalized a rule requiring drug sponsors to submit diversity action plans for clinical trials. This aims to ensure better representation of underrepresented groups in medical research. The rule takes effect in 2025.
The US Food and Drug Administration granted clearance to Apple's new hypertension detection feature for the Apple Watch on September 11, 2025. The feature, announced at Apple's early September product launch, will be available in 150 countries starting next week.
Riportato dall'IA
The US FDA has approved a new treatment for schizophrenia that promises fewer side effects than existing options. This marks a significant step forward in mental health medication.
US FDA approves first oral pill for thalassaemia anaemia
20 novembre 2025 04:09Paradromics receives FDA approval for brain implant trial
12 novembre 2025 22:22Poll, high‑profile cases fuel bipartisan push to revisit mail‑order abortion pill rules
11 novembre 2025 09:36FDA rimuove l'avvertimento black box dalla terapia ormonale per la menopausa
03 ottobre 2025 00:44Federal judge strikes down FDA limits on abortion pill
26 settembre 2025 00:23Coalition Opposes FDA's Proposed Ban on 7-OH Substance
22 settembre 2025 00:09FDA Approves Injectable Form of Merck's Keytruda
20 settembre 2025 00:15FDA Grants Accelerated Approval for First Barth Syndrome Treatment
15 settembre 2025 00:23FDA Approves New Hypertension Detection Device
13 settembre 2025 00:06FDA Approves Drug for Autoimmune Neuropathies